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Granulocytes from human eosinophilic donors were incubated with arachidonic acid or 15-hydroxyeicosatetraenoic acid 
(15-HETE) and stimulated with the ionophore A23187. The eicosanoids were extracted with reversed-phase cartridges 
and subjected to RP-HPLC analysis. When extracts from eosinophii-enriehed populations were analysed and compared 
with extracts from human neutrophils, three additional peaks were detected which coeluted with 15-hydroxy-z/13-trans- 
15H derivatives of leukotriene C 4, D 4 and E, in different HPLC systems. The recorded absorbance spectra of the eluted 
compounds and the standards were identical and showed a maximum at 307 nm which is characteristic for a conjugated 
tetraene system with a bathochromic shift by the sulfur moiety in ~t-position to the tetraene system. The compound which 
coeluted with the 15-hydroxy-LTC 4 standard was treated with y-glutamyltransferase andconverted to the corresponding 
leukotriene D4 derivative. The results indicate that interaction between the 5- and 15-1ipoxygenase pathways leads to 
the formation of a new series of arachidonie acid metabolites in human eosinophils. Since the biosynthetic route is similar 
to that of lipoxin A, and lipoxin B 4, we suggest the trivial names lipoxin C 4, D 4 and E~. 
Lipoxin; Leukotriene; Lipoxygenase; Eosinophil; Inflammation 
1. INTRODUCTION 
Recently, a new series of arachidonic acid me- 
tabolites was reported which is produced by the in- 
teraction of the 5- and the 15-1ipoxygenase path- 
way. The compounds contain a conjugated 
tetraene system and have been termed the lipoxins 
[1-5]. The lipoxins are biologically active com- 
pounds. LXA4 leads to superoxide anion genera- 
tion and degranulation i  human neutrophils [2], 
promotes chemotaxis [6], contracts lung paren- 
chymal strips [4] and activates protein kinase C in 
vitro [7]. Both LXA4 and LXB4 inhibit human 
killer cell activity [8,9]. 
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(15S)-hydroxy-5,6-epoxy-7,9,13-trans-11-cis- 
eicosatetraenoic acid was suggested to be the com- 
mon intermediate in the biosynthesis of lipoxin A4 
and B4 in human granulocytes [3,4] and LXA4 was 
found in extracts from human eosinophils 
stimulated with the ionophore A23187 and 
arachidonic acid [10]. Since it has been shown that 
GSH S-transferase is present in human eosinophils, 
which is responsible for the formation of leuko- 
triene Ca and its metabolites in these cells [11,12], 
it was of interest whether human eosinophils can 
release amino acid-containing lipoxins. This would 
give further evidence that (15S)-hydroxy-5,6- 
epoxyeicosatetraenoic ac d is the common inter- 
mediate in the lipoxin biosynthesis. The formed 
lipoxins would represent a new class of arachidonic 
acid metabolites i olated from biological sources. 
In this paper we describe the extraction, isolation 
and identification of amino acid-containing lipox- 
ins from human eosinophils. 15-Hydroxylated 
derivatives of leukotriene Ca, D4 and E4 were used 
as HPLC standards and prepared according to the 
method of 13rning and Hammarstr/Sm [13]. 
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2. EXPERIMENTAL  
2.1. Materials 
The lipoxin standards LXA4, 6S-LXA4, l l-trans-LXA4, 
6S-11-trans-LXA4, LXB4, 14S-LXB4, 8-trans-LXB4 and 
14S-8-trans-LXB4 were generous gifts from Dr J. Rokach 
(Merck Frosst, Quebec, Canada), leukotriene C4, I)4 and E4 and 
other lipoxygenase metabolites were obtained from Paesel 
GmbH (Frankfurt, FRG). Arachidonic acid, soybean lipoxy- 
genase, 7-glutamyltransferase, GSH peroxidase, trifluoroacetic 
acid and ionophore A23187 (free acid) were purchased from 
Sigma (St. Louis, MO, USA). All solvents used were of 
analytical grade. PMI6 (Serva) supplemented with human 
albumin (0.1%), glucose (0.1070) and Ca 2+ (1 mM served as in- 
cubation buffer. 15-HETE was either obtained from Paesel 
GmbH or prepared according to the method of Hamberg and 
Samuelsson [14]. 
2.2. Methods 
2.2.1. Preparation of lipoxin standards 
LTD4 or LTE4 (2.5/~g) were incubated with 20/zg soybean 
lipoxygenase (2500 units) in 1 ml PBS buffer, pH 7.4, at room 
temperature under vigorous shaking. 100/zg soybean lipoxy- 
genase were used to transform LTC4. The reaction was followed 
by UV spectrophotometry with scanning between 250 and 
350 nm. When the reaction was complete, either GSH perox- 
idase (20/~g, 2.8 units) and GSH (1 mM) or 500)~1 methanol 
and sodium borhydride were added to reduce the formed hydro- 
peroxides and the mixture was incubated at room temperature 
for 15 rain. Then, GSH peroxidase reaction was stopped with 
500/zl methanol and when sodium borhydride was used, the 
mixture was acidified to pH 6 with HCI, extracted and analysed 
as described below. 
2.2.2. Cell isolation and incubation 
Suspensions of human polymorphonuclear leukocytes were 
prepared according to the method of Hjorth et al. [15]. The 
suspensions obtained from the eosinophilic donors contained 
more than 50°70 eosinophils. The polymorphonuclear leukocytes 
(5 ml, 4.0 x 10 7 cells/ml) were preincubated with 15-HETE 
(20/~M) for 2 min. The reaction was started with ionophore 
A23187 (5/zM). After 5 min (unless otherwise mentioned in the 
text), the reaction was stopped with methanol, the tubes were 
chilled on ice, diluted with buffer to a methanol content lower 
than 30070, centrifuged (800 x g, 10 min) and extracted. 
2.2.3. Extraction procedure 
The lipoxins were extracted according to the method escrib- 
ed in [16,17]. The extraction procedure in brief: Baker C-18 dis- 
posable columns were conditioned with 2 ml methanol, 2 ml 
water, 2 ml of 0.1 °70 aqueous EDTA solution and 2 ml water. 
The samples were then applied to the columns and washed with 
3 ml water and 3 ml of 25070 methanol. Finally, the lipoxins 
were eluted with 100070 methanol, the extract was evaporated to
dryness with a stream of nitrogen and resuspended in a small 
volume of methanol. 10/zl of this solution were injected into the 
HPLC apparatus. 
2.2.4. Analytical methods 
HPLC was carried out on a Waters Radial-Pak cartridge 
(100 mm x 5 mm i.d.) packed with Novapak C-18 (particle size 
4/~m) which was obtained from Waters (Eschborn, FRG). The 
solvent system was either methanol/water/trifluoroacetic acid 
or acetonitrile/water/trifluoroacetic acid. A flow rate of 1.2 ml 
was used and the peaks were monitored with a Waters 481 UV 
detector set at 380 nm. UV spectra were recorded with a 
Beckman DU-50 spectrophotometer connected on line with the 
HPLC equipment. 
2.2.5. Conversion of lipoxin C4 to 1)4 
The LXC4 extract was evaporated to dryness, 87.5/~1 PBS 
buffer, pH 7.5, 10/zl 7-glutamyltransferase olution 
(200/~g/ml, 24 U/mg) and 2.5/~1 cysteine solution (final con- 
centration 100~M) were added and incubated for 30 min at 
25°C. Then, 20/~1 of this solution were directly analysed by 
HPLC. 
3. RESULTS AND DISCUSSION 
Human eos inoph i l s  were incubated  wi th  
15-HETE and  s t imu la ted  w i th  the  ionophore  
A23187 for  5 min .  F ig . lA  shows  a chromatogram 
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Fig. 1. RP-HPLC chromatograms of the lipoxins extracted from 
human eosinophils after incubation of the cells with ionophore 
for 5 min. The column was eluted with 66:34:0.008 
methanol/water/trifluoroacetic ac d (A) and 44: 56: 0.008 
acetonitrile/water/trifluoroacetic acid (B). The wavelength 
selector of the detector was set at 308 nm. 
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Fig.2. UV-spectrum of peak I (dotted line) and LX-standard 
(straight line). The spectrum was recorded in 62:38:0.008 
methanol/water/trifluoroacetic acid. 
obtained after extraction of the lipoxins with 
reversed-phase cartridges. The chromatogram 
shows 3 peaks that did not coelute with any HPLC 
standard of the LXA or LXB series. The retention 
times of these peaks were strongly affected by the 
trifluoroacetic acid concentration i the mobile 
phase, which is typical for arachidonic acid metab- 
olites containing an amino acid residue [18]. The 
peaks showed UV spectra which were similar to the 
spectra obtained from LXA4 and LXB4, except for 
a bathochromic shift of 6 nm leading to a max- 
imum at 307 nm with shoulders at 294 and 321 nm 
(fig.2). Since these spectra are typical for com- 
pounds having a conjugated tetraene structure with 
an allylic thioether substituent [13], there was 
evidence that these compounds are formed from 
15-hydroxy-5,6-epoxyeicosatetraenoic cid by the 
action of the GSH S-transferase which is present in 
human eosinophils. This would lead to the 
(5S, 15 S)-dihydroxy-6-glutathionyl-7,9,11,13- 
eicosatetraenoic acid and the corresponding metab- 
olites of the D- and E-series (see fig.4). Therefore, 
HPLC standards of these compounds were 
prepared as described in section 2.2. Peak I co- 
eluted with the (5S, 15S)-dihydroxy-(6R)-S- 
glutathionyl-eicosatetraenoic acid standard, while 
the peaks II and III coeluted with the correspon- 
ding 15-hydroxy derivative of LTE4 and LTD4, 
respectively (fig.lA). Both HPLC standards and 
the peaks I, II and III showed the same UV spectra 
(fig.2). For peak identification, a second mobile 
phase consisting of water/acetonitrile/trifluoro- 
acetic acid was used. Under these chromatographic 
conditions, the amino acid-containing HPLC 
standards are widely separated from each other 
(retention times: 15-hydroxy-LTC4 3.26 min, 
15-hydr0xy-LTE4 5.08 min, 15-hydroxy-LTD4 
8.27 min with 44: 56 • 0.008 acetonitrile/water/tri- 
fluoroacetic acid and 7.16, 10.96 and 19.69 min 
with 36:64:0.008, respectively). Fig.lB shows a 
HPLC chromatogram of the lipoxins extracted 
from human eosinophils and eluted with 
44: 56: 0.008 acetonitrile/water/trifluoroacetic 
acid as the mobile phase. Under these chromato- 
graphic conditions, the 15-hydroxy-LTC4 
derivative lutes at very short retention times and 
cochromatographs with an LXA4 isomer. 
The fraction (peak I, fig.lA) eluting with the 
same retention time as the 15-hydroxy-LTC4 stand- 
ard under the chromatographic conditions describ- 
ed in fig. 1A was pooled and rechromatographed in 
the acetonitrile/water system. Under these condi- 
tions, peak I coeluted with the 15-hydroxy-LTC4 
standard as well (chromatogram not shown). For 
further confirmation of the GSH moiety, the 
material was treated with 7-glutamyltransferase. 
The material was metabolised by this enzyme and a 
new peak appeared which coeluted with the 
15-hydroxy-A 13_trans_ 15H-LTD4 standard. There- 
fore, it can be concluded, that the compound refer- 
red to as peak I is (5,15S)-dihydroxy-6- 
glutathionyl-7,9,11,13-eicosatetraenoic acid. Since 
the stereochemistry of the 15-hydroxylated LTC4 
standard was assigned as (5S, 15S)-dihydroxy-(6R)- 
S-glutathionyl-7,9,13-trans- 11-cis-eicosatetraenoic 
acid [13], the configuration of the coeluting com- 
pound (peak I) is probably the same. However, an 
all trans double bond geometry or other configura- 
tions at C-5 or C-6 would theoretically be possible 
but are rather unlikely because of the stereo- 
specificity of the enzymes involved in the biosyn- 
thesis of the compounds. Moreover, the capability 
of the column to separate the cis from the cor- 
responding trans isomers (e.g. LTC4 from 
11-trans-LTC4, LXA4 from 11-trans-LXA4, LXB4 
145 
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Fig.3. RP-HPLC chromatograms of the lipoxins extracted from 
eosinophils after incubation of the cells with ionophore for 
15 min. The column was eluted with 62:38:0.008 
rnethanol/water/trifluoroacetic ac d (A) and 36: 64 : 0.008 
acetonitrile/water/trifluoroacetic acid (B). 
from 8-trans-LXB4) and the high resolution of the 
column makes it rather unlikely that the C-5 or C-6 
epimers or the all-trans isomer coelute xactly with 
the HPLC standard. 
In order to get higher quantities of the metabo- 
lites of LXC4, the incubation time was increased to 
15 min. Fig.3A shows a chromatogram of the 
tetraenes, extracted from eosinophils under these 
conditions. There, only minor amounts of peak I 
were detected and the compound coeluting with 
15-hydroxy-AiLtrans-15H-LTE4 was the major 
product. The fraction was collected and re- 
chromatographed in the acetonitrile/water system. 
In both HPLC systems, peak II coeluted with the 
15-hydroxy-LTE4 standard so that the compound 
can be assigned as 15-hydroxy-LTE4, a metabolite 
which can be formed from 15-hydroxy-LTC4 by 
the action of the 7-glutamyltransferase ndthe di- 
peptidase in human eosinophils. Fig.3B shows a 
chromatogram of the tetraenes obtained when 
acetonitrile/water/trifluoroacetic acid was used as 
mobile phase. 
Peak III coeluted in both HPLC systems with 
15-hydroxy-A1Ltrans-15H-LTD4. he amounts of 
this compound were much less than those of peaks 
I and II released by the cells after 5 and 15 min. 
This is in agreement with the metabolism of the 
amino acid-containing leukotrienes in the cells 
under our assay conditions. There, only minor 
amounts of LTD4 were released which may be due 
to the rapid metabolism of LTD4 to LTE4.1-3°70 of 
the added 15-HETE was converted into lipoxins 
and in the presence of 20/zM exogenous 15-HETE, 
peak I (corresponding to 15-hydroxy-LTC4) was 
the major arachidonic acid metabolite released 
from the cells after stimulation with the ionophore. 
Since human eosinophils possess a 15-1ipoxy- 
genase, it was of interest whether arachidonic acid 
can be transformed to these metabolites by the 
cells. Therefore, human eosinophils were in- 
cubated with either arachidonic acid (50/~M) and 
ionophore or with ionophore alone. 
In incubations with arachidonic acid and iono- 
phore, the same pattern of tetraenes was observed 
as in the incubations with 15-HETE and ionophore 
(chromatogram not shown) and no additional 
peaks were detected, so that a significant forma- 
tion of 5,15-dihydroxy-14-GSH adducts can be rul- 
ed out. These compounds could be formed via the 
5-hydroxy-14,15-epoxy-eicosatetraenoic acid, an 
intermediate which cannot be produced from 
15-HETE but from 15-HPETE, which is present in 
arachidonic acid- and ionophore-stimulated cells. 
The failure to detect hese compounds i in agree- 
ment to the finding that incubation with either 
15-HETE or 15-HPETE leads to the same LX spec- 
trum in granulocytes [3,4], so that the 15-hydroxy- 
5,6-epoxy-eicosatetraenoic acid and not the 
14,15-epoxide must be regarded as the common 
precursor of lipoxins in human granulocytes. 
Moreover, no 14-GSH isomers of leukotrienes 
were isolated from biological material up to now, 
which makes it rather unlikely that there is an en- 
zyme in eosinophils which can transform 
arachidonic acid-derived 14,15-epoxides to 
14-GSH adducts. Taken together, these two facts 
may explain the absence of 14-GSH adducts in our 
incubations. 
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The amounts of tetraenes formed in the presence 
of arachidonic acid were much lower than in the 
presence of exogenous 15-HETE. This might be 
due to the lower amount of 15-HETE which is 
available for the formation of the 15-hydroxy-LTs 
when the cells were incubated without added 
15-HETE. In the incubations with ionophore alone 
(without 15-HETE and without arachidonic acid), 
neither 15-HETE nor any tetraenes were detected 
and the leukotrienes LTC4, D4 and E4 were the pre- 
dominant lipoxygenase metabolites. The lack of 
15-HETE formation under these conditions is in 
agreement to other reports [12,19] and may be due 
to the lacking availability of arachidonic acid for 
the 15-1ipoxygenase when the cells are stimulated 
with the ionophore alone. 
However, it becomes evident from these results, 
that the formation of these metabolites i  closely 
related to the presence of 15-HETE and that the 
presence of this metabolite is responsible for the 
ratio of LTC4 and 15-hydroxy-LTC4. High 
15-HETE concentrations lead to the predominant 
formation of 15-hydroxy-LTC4, while low 
15-HETE concentrations lead to the predominant 
release of leukotrienes. These results and the fact 
that no tetraenes were detected in samples contain- 
ing no 15-HETE but high amounts of LTC4, 04 
and E4 (samples of cells stimulated with ionophore 
alone) clearly demonstrate hat these tetraenes are 
not formed by the attack of the eosinophil 
15-1ipoxygenase on leukotriene C4, D4 and E4. 
Therefore, one can conclude that these compounds 
are produced via the 15-hydroxy-5,6-epoxy-eicosa- 
tetraenoic acid like LXA4 and LXB4. Since the bio- 
synthetic route is similar to that of LXA4 and 
LXB4, we suggest the trivial names lipoxin C4, D4 
and E4. The scheme for the formation of LXC4, 
LXD4 and LXE4 is given in fig.4. Interaction of the 
5- and the 15-1ipoxygenase pathway leads to the 
(15S)-hydroxy-5,6-epoxy-7,9,13 ,-trans- 11 -cis- 
eicosatetraenoic a id which is transformed to 
lipoxin C4 by the eosinophil-derived GSH S-trans- 
ferase. The formed LXC4 can be further metabolis- 
ed by the 7-glutamyltransferase and dipeptidase to 
LXD4 and LXE4. 
Previous tudies have reported that LTC4 and its 
metabolites are the predominant 5-1ipoxygenase 
products generated in human eosinophils. In the 
present study, we have shown that human eosino- 
phils release a novel series of lipoxins in the 
OOH 
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I S - hpoxygenQst 
f   OOH] ( OH ] 
LXA(.. LXB, ~H2--~ HCONHEH2 COOH 
NHCO(CHz) 2 CH--C00H 
COOH INH 2 
OH 
I ~'- glu tomy& tron~ f mr ase 
CHz--CHCONHZH2 COOH 
I I 
S NH2 
~ C O O H  lipoxin O~. 
OH 
I dlpeptidQse 
~ H2--EHCOOH 
r 
NH2 
COOH 
OH 
Fig.4. Scheme for the formation of lipoxin C4, D4 and E4 in 
human eosinophils. 
[ipoxin C~ 
lipoxin E~ 
presence of the 15-1ipoxygenase metabolite 
15-HETE. Since 15-HETE can be released from 
eosinophils under certain conditions [12] and from 
other cells [20,21] and tissues [22], there is strong 
evidence that these compounds are also produced 
in eosinophils or by transcellular biosynthesis [23] 
in vivo. Therefore, it is of interest to elucidate the 
biological activities of this new series of lipoxins 
and their physiological and pathophysiological 
role. Since LXA4 and LXB4 show biological ac- 
tivities distinct from leukotriene B4, this new series 
of lipoxins may also show other biological effects 
than the amino acid-containing leukotrienes. 
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